Kymab names Groendahl CEO, Chiswell as chair
This article was originally published in Scrip
Biopharmaceutical firm Kymab, which develops fully human monoclonal antibodies, has named Dr Christian Groendahl and Dr David Chiswell chief executive officer and chair of the board, respectively. Dr Groendahl joins the Cambridge, UK-based firm from Zealand Pharma where he was chief scientific officer. Meanwhile Dr Chiswell has previously been chair of a number of biotechnology companies – including Nabriva Therapeutics, Sosei, and Daniolabs – and is currently non-executive chair of Albireo Pharma and a director of Nabriva Therapeutics. He joined the Kymab board in 2012. Both appointments are effective from 16 September 2013.
You may also be interested in...
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.